Skip to content
2000
Volume 25, Issue 8
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Crucial for understanding liver cancer patients overall health outcomes. This research aimed to assess the CVM risk of them.

Methods and Materials

Data sourced from the Surveillance, Epidemiology, and End Results (SEER) database encompassing liver cancer diagnoses from 2000 to 2017 were utilized. The standardized mortality rate (SMR) was computed using general population reference data, and multivariate competing risk models were employed for analysis.

Results

Analysis of 70,733 liver cancer patient records revealed 1,954 instances of CVM. The overall CVM SMR for liver cancer patients was 12.01 (95% CI: 11.48-12.55). Various demographic and clinical factors, including sex, race, age, year of diagnosis, pathological type, general stage, treatment modalities, and matrimonial status, emerged as liver cancer patients` independent predictors of CVM.

Conclusion

Liver cancer patients have a notably heightened susceptibility to cardiovascular mortality (CVM) in contrast to the general populace. It is imperative to promptly recognize high-risk subcategories and execute tailored cardiovascular interventions as crucial measures to bolster survival rates within this cohort of patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096321687240912111652
2024-10-28
2025-12-15

  • From This Site

    /content/journals/ccdt/10.2174/0115680096321687240912111652
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. ShiJ.F. CaoM. WangY. Is it possible to halve the incidence of liver cancer in China by 2050?Int. J. Cancer202114851051106510.1002/ijc.3331332997794
     [Google Scholar]
  3. RothG.A. AbateD. AbateK.H. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017.Lancet2018392101591736178810.1016/S0140‑6736(18)32203‑730496103
     [Google Scholar]
  4. KochanekK.D. MurphyS.L. XuJ. AriasE. Deaths: Final Data for 2017.Natl. Vital Stat. Rep.201968917732501199
     [Google Scholar]
  5. GaitanidisA. SpathakisM. TsalikidisC. AlevizakosM. TsarouchaA. PitiakoudisM. Risk factors for cardiovascular mortality in patients with colorectal cancer: A population-based study.Int. J. Clin. Oncol.201924550150710.1007/s10147‑018‑01382‑x30604158
     [Google Scholar]
  6. KoeneR.J. PrizmentA.E. BlaesA. KonetyS.H. Shared risk factors in cardiovascular disease and cancer.Circulation2016133111104111410.1161/CIRCULATIONAHA.115.02040626976915
     [Google Scholar]
  7. FelixA.S. BowerJ.K. PfeifferR.M. RamanS.V. CohnD.E. ShermanM.E. High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database.Int. J. Cancer2017140355556410.1002/ijc.3047027741565
     [Google Scholar]
  8. SunS. WangW. HeC. Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry‐Based Analysis.Oxid. Med. Cell. Longev.202120211998581410.1155/2021/998581434257826
     [Google Scholar]
  9. FungC. FossaS.D. MilanoM.T. SahasrabudheD.M. PetersonD.R. TravisL.B. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.J. Clin. Oncol.201533283105311510.1200/JCO.2014.60.365426240226
     [Google Scholar]
  10. WangQ. JiangC. ZhangY. Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: A surveillance, epidemiology and end results (SEER) analysis.Leuk. Lymphoma20206151147115710.1080/10428194.2019.171107431985308
     [Google Scholar]
  11. AustinP.C. FineJ.P. Practical recommendations for reporting F ine‐ G ray model analyses for competing risk data.Stat. Med.201736274391440010.1002/sim.750128913837
     [Google Scholar]
  12. WangS. GeC. ZhangJ. Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study.J. Cardiovasc. Dev. Dis.20229825510.3390/jcdd908025536005419
     [Google Scholar]
  13. FangF. KeatingN.L. MucciL.A. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: Cohort study in the United States.J. Natl. Cancer Inst.2010102530731410.1093/jnci/djp53720124521
     [Google Scholar]
  14. YeY. OtahalP. MarwickT.H. WillsK.E. NeilA.L. VennA.J. Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population‐based study.Cancer2019125344245210.1002/cncr.3180630311655
     [Google Scholar]
  15. WongM.D. ChungA.K. BoscardinW.J. The contribution of specific causes of death to sex differences in mortality.Public Health Rep.2006121674675410.1177/00333549061210061517278410
     [Google Scholar]
  16. LiuF. LiuY. SunX. Race- and sex-specific association between alcohol consumption and hypertension in 22 cohort studies: A systematic review and meta-analysis.Nutr. Metab. Cardiovasc. Dis.20203081249125910.1016/j.numecd.2020.03.01832446870
     [Google Scholar]
  17. ArnettD.K. BlumenthalR.S. AlbertM.A. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A.Circulation2019140e596e64610.1161/CIR.000000000000067830879355
     [Google Scholar]
  18. MessnerB. BernhardD. Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis.Arterioscler. Thromb. Vasc. Biol.201434350951510.1161/ATVBAHA.113.30015624554606
     [Google Scholar]
  19. AizerA.A. ChenM.H. McCarthyE.P. Marital status and survival in patients with cancer.J. Clin. Oncol.201331313869387610.1200/JCO.2013.49.648924062405
     [Google Scholar]
  20. GalloL.C. TroxelW.M. MatthewsK.A. KullerL.H. Marital status and quality in middle-aged women: Associations with levels and trajectories of cardiovascular risk factors.Health Psychol.200322545346310.1037/0278‑6133.22.5.45314570528
     [Google Scholar]
  21. KubzanskyL.D. HuffmanJ.C. BoehmJ.K. Positive Psychological Well-Being and Cardiovascular Disease.J. Am. Coll. Cardiol.201872121382139610.1016/j.jacc.2018.07.04230213332
     [Google Scholar]
  22. EslerM. Mental stress and human cardiovascular disease.Neurosci Biobehav Rev201774Pt B2697610.1016/j.neubiorev.2016.10.01127751732
     [Google Scholar]
  23. MohanN. JiangJ. DokmanovicM. WuW.J. Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers.Antib. Ther.201811131710.1093/abt/tby00330215054
     [Google Scholar]
  24. ChoueiriT.K. MayerE.L. JeY. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.J. Clin. Oncol.201129663263810.1200/JCO.2010.31.912921205755
     [Google Scholar]
  25. AghelN. DelgadoD.H. LiptonJ.H. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Preventive strategies and cardiovascular surveillance.Vasc. Health Risk Manag.20171329330310.2147/VHRM.S10887428831263
     [Google Scholar]
  26. EvansM.A. SanoS. WalshK. Cardiovascular Disease, Aging, and Clonal Hematopoiesis.Annu. Rev. Pathol.202015141943810.1146/annurev‑pathmechdis‑012419‑03254431689371
     [Google Scholar]
  27. JaiswalS. EbertB.L. Clonal hematopoiesis in human aging and disease.Science20193666465eaan467310.1126/science.aan467331672865
     [Google Scholar]
  28. ParkS.J. BejarR. Clonal Hematopoiesis in Aging.Curr. Stem Cell Rep.20184320921910.1007/s40778‑018‑0133‑930854305
     [Google Scholar]
  29. MeijersW.C. MaglioneM. BakkerS.J.L. Heart Failure Stimulates Tumor Growth by Circulating Factors.Circulation2018138767869110.1161/CIRCULATIONAHA.117.03081629459363
     [Google Scholar]
  30. HasinT. GerberY. McNallanS.M. Patients with heart failure have an increased risk of incident cancer.J. Am. Coll. Cardiol.2013621088188610.1016/j.jacc.2013.04.08823810869
     [Google Scholar]
  31. BankeA. SchouM. VidebækL. Incidence of cancer in patients with chronic heart failure: A long‐term follow‐up study.Eur. J. Heart Fail.201618326026610.1002/ejhf.47226751260
     [Google Scholar]
  32. BroustasC.G. LiebermanH.B. DNA damage response genes and the development of cancer metastasis.Radiat. Res.2014181211113010.1667/RR13515.124397478
     [Google Scholar]
  33. PfefferT.J. PietzschS. Hilfiker-KleinerD. Common genetic predisposition for heart failure and cancer.Herz202045763263610.1007/s00059‑020‑04953‑932542459
     [Google Scholar]
  34. CuiH. ZuoS. LiuZ. The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs.Sci. Adv.2020642eabb854310.1126/sciadv.abb854333055159
     [Google Scholar]
  35. HabibianM. LyonA.R. Monitoring the heart during cancer therapy.Eur. Heart J. Suppl.201921M44M4910.1093/eurheartj/suz23031908616
     [Google Scholar]
/content/journals/ccdt/10.2174/0115680096321687240912111652
Loading
Cardiovascular Mortality Risk Among Patients with Liver Cancer: A SEER Database Study
Curr. Cancer Drug Targets< 25, 1000 (2025); https://doi.org/10.2174/0115680096321687240912111652
/content/journals/ccdt/10.2174/0115680096321687240912111652
/content/journals/ccdt/10.2174/0115680096321687240912111652
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Cardiovascular mortality; competing risk regression; cumulative mortality curves; cumulative mortality curves standardized mortality ratios; liver cancer; SEER database; standardized mortality ratios

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test